Publications by authors named "Christopher Pelligra"

Claim this Profile
P
Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.
Joslyn S Kirby, Linnea Thorlacius, Jérémy Lambert, Valerie Ciaravino, Robert Rolleri, Christopher G Pelligra

Br J Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data.
John R Ingram, Jérémy Lambert, Valerie Ciaravino, Robert Rolleri, Ingrid Pansar, Christopher G Pelligra

Dermatol Ther (Heidelb)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms.
Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, Aylin Yucel, Roberto Latagliata, Christopher G Pelligra

Front Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial.
Ali T Taher, Khaled M Musallam, Vip Viprakasit, Antonis Kattamis, Jennifer Lord-Bessen, Christopher G Pelligra

BMJ Open· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis.
Laure Gossec, Ana-Maria Orbai, Laura C Coates, Dafna D Gladman, Alexis Ogdie, Christopher G Pelligra

RMD Open· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.
Lisa J McGarry, Zahra Bhaiwala, Andrea Lopez, Conor Chandler, Christopher G Pelligra

PLoS One· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.
Ali T Taher, Khaled M Musallam, Vip Viprakasit, Antonis Kattamis, Jennifer Lord-Bessen, Christopher Pelligra

BMJ Open· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Valeria Santini, Aristoteles Giagounidis, Christopher G Pelligra, Conrado Franco-Villalobos, Derek Tang

Clin Lymphoma Myeloma Leuk· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
Richard B Warren, Alice B Gottlieb, Joseph F Merola, Llenalia Garcia, Christopher Cioffi, Christopher Pelligra

Dermatol Ther (Heidelb)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
Alice B Gottlieb, Richard B Warren, Matthias Augustin, Llenalia Garcia, Christopher Cioffi, Christopher Pelligra

Adv Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Jaime L Rubin, Lasair O'Callaghan, Christopher Pelligra, Michael W Konstan, Alexandra Ward

Ther Adv Respir Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Christopher G Pelligra, Kejal Parikh, Shien Guo, Conor Chandler, Jorge Mouro

Clin Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections.
Nikhil Revankar, Alexandra J Ward, Christopher G Pelligra, Thitima Kongnakorn, Weihong Fan

J Med Econ· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.
Shien Guo, Christopher Pelligra, Catherine Saint-Laurent Thibault, Luis Hernandez, Anuraag Kansal

Pharmacoeconomics· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis